A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose with Peginterferon alfa-2A and Ribavirin in patients with hepatitis C genotype 1

Lisa N. Patel, MD, S. E. Keller, PhD, Michael Demyen, MD

Teaching Residents Quality Improvement: An Innovative QA/QI Initiative in the Internal Medicine Residency Program: Meeting the ACGME’s Requirement for

Daniel Zakhary MD, PhD, Eyad Alhaj MD, Robert Berkowitz, MD, PhD

Dorothy Castro MD; Roger Keshav MD; Lisa Dever MD; Patricia Kloser MD

Matthew J Michaels, DO, Edward Andraos, BA, David Bleich, MD

V. Dave, B.Kasimis, V.Chang, M.Gonzalez, S.Srinivas, F.Zhong, B.Crump, L.Duque, E.Paz, M.McPherson, J.Einhorn

AA Amyloidosis in a Patient with Ankylosing Spondylitis: Renal Manifestations

R. Khianey, R. Shapiro, L. Gang, P. Kattouf, H. Jyonouchi

Immune Abnormalities in Chronic Pain Syndrome (CPS) With Unknown Etiology

Familial Presentation of Sensorineural Hearing Loss, Aortic Insufficiency and Positive Myelin Protein Zero Antibody:

Provides Safe & Effective Alternative To Liver Transplant In Acute Budd Chiari Syndrome

with Peginterferon alfa-2A and Ribavirin in patients with hepatitis C genotype 1

"Post-transcriptional Regulation of Tac1 in Breast Cancer Cells"

"IL-28B rs12979860 Polymorphism Modulates Hepatic Fibrosis"